Isothiazolinone allergy in Europe on decline but rising in USA due to differences in regulation: JAMA

For this purpose, the researchers conducted a retrospective analysis of the ESSCA (European Surveillance System on Contact Allergies), the North American Contact Dermatitis Group, and the IVDK (Information Network of Departments of Dermatology) databases, including data from patients presenting for patch testing at clinics in Europe and North America.

Exposures included patch tests for MCI/MI and MI. The team determined the prevalence of allergic contact dermatitis to MI and MCI/MI (main outcome measures).

The study led to the following findings:

• Participating sites in North America and Europe patch-tested 226 161 people to MCI/MI and 118 779 to MI from 2009 to 2018.
• In Europe, positivity to methylchloroisothiazolinone/methylisothiazolinone peaked during 2013 and 2014 at 5.4% (IVDK) and 7.6% (ESSCA) before decreasing to 3.2% (IVDK) and 4.4% (ESSCA) in 2017 and 2018.
• During 2017 and 2018, positive reactions to methylisothiazolinone were 3.4% (IVDK) and 5.5% (ESSCA).
• In North America, through the study period, the positivity to MCI/MI frequency rose steadily, reaching 10.8% for MCI/MI during 2017 and 2018.
• During 2017 and 2018, positive reactions to methylisothiazolinone were 15.0%.

"Our study's findings indicate that in contrast to the continued increase of isothiazolinone allergy in North America, there is a decline in Europe," the researchers wrote. "This trend corresponds with earlier and more stringent government regulation of methylisothiazolinone in Europe."

Reference:

Reeder MJ, Warshaw E, Aravamuthan S, et al. Trends in the Prevalence of Methylchloroisothiazolinone/Methylisothiazolinone Contact Allergy in North America and Europe. JAMA Dermatol. Published online January 18, 2023. doi:10.1001/jamadermatol.2022.5991